Instil Bio is a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. Co. develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Co.'s TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. Co. is also developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. The TIL stock yearly return is shown above.
The yearly return on the TIL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TIL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|